Skip to main content.

Completed Pulmonary Hypertension Trials

AC-055-503 - OPUS Registry

US-based, observational, drug registry of Opsumit® (macitentan) new users in clinical practice

     More Information


AC-0550510 - OrPHeUS

Multicenter, retrospective chart review of first-time Opsumit® (macitentan) users in the United States

     More Information 


BIA-51058-203-UpRight

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase IIb Study with Open-Label Extension to Demonstrate the Efficacy and Safety of Zamicastat (BIA 5-1058) as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH) Patients with Right Ventricular (RV) Systolic Dysfunction. 


CXA-10-301 - PRIMEx

Phase 2 Multicenter, Double-Blind, Placebo Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)

     More Information


CXA-10-2302 - PRIMEx OLE

A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301

     More Information 


LTI-301 - INSPIRE

A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients

     More Information


PB1046-PT-CL-0004-VIP

A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension.  

  • Enrollment Status: Terminated
  • Study Type: Interventional (Clinical Trial)
  • Intervention/Treatment: Pemziviptadil (PB1046) or Placebo
  • Sponsor: PhaseBio
  • PI: Leslie A. Spikes, M.D.

PB1046-PT-CL-0004-VIP-EXTEND

A Long-Term, Open Label Extension Study of PB1046 Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Stuidy PB1046-PT-CL-0004.  

  • Enrollment Status: Terminated
  • Study Type: Interventional (Clinical Trial)
  • Intervention/Treatment: Pemziviptadil (PB1046) or Placebo
  • Sponsor: PhaseBio
  • PI: Leslie A. Spikes, M.D.

REPLACE - Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy

A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal.

     More Information

 


RIN-PH-201 - INCREASE

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

     More Information


RIN-PH-202 - INCREASE OLE

An Open-Label Extension Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

     More Information

 


TDE-HF-301 - SouthPaw

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

     More Information

 


TDE-HF-302 - SouthPaw OLE

An Open-label Extension Study of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) Associated with Heart Failure with Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301

     More Information 

 


U.S. CTEPH Registry

The U.S. CTEPH Registry is a multicenter, observational, U.S.-based study of the clinical course and treatment of patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.

  • Enrollment Status: Completed
  • Study Type: Observational 
  • PI: Timothy Williamson, MD, FCCP

     More Information

Internal Medicine

University of Kansas Medical Center
Internal Medicine
Pulmonary, Critical Care, and Sleep Medicine Division
Mailstop 3007
3901 Rainbow Boulevard
Kansas City, KS 66160
Phone: 913-588-6045